MedTrace Logo

Long-term Surival of GIST Patients ≥ 10 Years on Imatinib

NCT04097093 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-09-02

No results posted yet for this study

Summary

This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828". With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Neeltje Steeghs · NKI - Antoni van Leeuwenhoekziekenhuis

  • Axel Le Cesne · Gustave Roussy, Cancer Campus, Grand Paris

  • Ingrid Desar · Radboud University Medical Center Nijmegen

  • Olga Husson · Radboud University Medical Center Nijmegen

Eligibility

Min Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-12-01
Completion
2021-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04097093 on ClinicalTrials.gov